Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system
{{output}}
Background: Ribociclib plus letrozole significantly improves survival in HR+/HER2- advanced-stage or metastatic postmenopausal breast cancer (BC) patients. Aim: ... ...
